Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Allogene Therapeutics, Inc.”

16 pharma patents match "Allogene Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 16
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 16 pharmaceutical patents matching "Allogene Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

16 results for “Allogene Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12404315

    Protease-activating CD45-gate CAR

    Allogene Therapeutics, Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  2. US 12365873

    Methods for transducing immune cells

    Allogene Therapeutics, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  3. US 12295362

    Formulations and processes for CAR T cell drug products

    Allogene Therapeutics, Inc. · Granted May 13, 2025 · Expires May 8, 2045

    granted
  4. US 12221462

    Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells

    Allogene Therapeutics, Inc. · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  5. US 12215347

    Chimeric antigen receptors with enhanced signaling and activities and uses thereof

    Allogene Therapeutics, Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  6. US 12163153

    Methods of manufacturing allogeneic CAR T cells

    Allogene Therapeutics, Inc. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  7. US 12163169

    Inducible chimeric cytokine receptors

    Allogene Therapeutics, Inc. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  8. US 12104188

    Modified caspase-9 polypeptides and methods of use thereof

    Allogene Therapeutics, Inc. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  9. US 12043655

    Constitutively active chimeric cytokine receptors

    Allogene Therapeutics, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  10. US 12036243

    BCMA CAR-T cells with enhanced activities

    Allogene Therapeutics, Inc. · Granted Jul 16, 2024 · Expires Jul 11, 2044

    granted
  11. US 11896617

    Polynucleotides encoding rituximab-resistant chimeric antigen receptors

    Allogene Therapeutics, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  12. US 11786553

    Chimeric cytokine receptors bearing a PD-1 ectodomain

    Allogene Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  13. US 11732041

    Antibodies against 4G7-derived chimeric antigen receptors

    Allogene Therapeutics, Inc. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  14. US 11673953

    DLL3 targeting chimeric antigen receptors and binding agents

    Allogene Therapeutics, Inc. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  15. US 11326156

    Modified caspase-9 polypeptides and methods of use thereof

    Allogene Therapeutics, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted
  16. US 11072644

    Inhibitory chimeric antigen receptors

    Allogene Therapeutics, Inc. · Granted Jul 27, 2021 · Expires Jul 22, 2041

    granted